JP2021512894A5 - - Google Patents

Info

Publication number
JP2021512894A5
JP2021512894A5 JP2020542552A JP2020542552A JP2021512894A5 JP 2021512894 A5 JP2021512894 A5 JP 2021512894A5 JP 2020542552 A JP2020542552 A JP 2020542552A JP 2020542552 A JP2020542552 A JP 2020542552A JP 2021512894 A5 JP2021512894 A5 JP 2021512894A5
Authority
JP
Japan
Prior art keywords
composition
subject
compound according
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
JP2020542552A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019156929A5 (https=
JP2021512894A (ja
JP7397797B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016503 external-priority patent/WO2019156929A1/en
Publication of JP2021512894A publication Critical patent/JP2021512894A/ja
Publication of JPWO2019156929A5 publication Critical patent/JPWO2019156929A5/ja
Publication of JP2021512894A5 publication Critical patent/JP2021512894A5/ja
Priority to JP2023203652A priority Critical patent/JP2024023490A/ja
Application granted granted Critical
Publication of JP7397797B2 publication Critical patent/JP7397797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542552A 2018-02-07 2019-02-04 治療用化合物および組成物 Active JP7397797B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023203652A JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627435P 2018-02-07 2018-02-07
US62/627,435 2018-02-07
PCT/US2019/016503 WO2019156929A1 (en) 2018-02-07 2019-02-04 Therapeutic compounds and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203652A Division JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Publications (4)

Publication Number Publication Date
JP2021512894A JP2021512894A (ja) 2021-05-20
JPWO2019156929A5 JPWO2019156929A5 (https=) 2022-02-14
JP2021512894A5 true JP2021512894A5 (https=) 2022-02-14
JP7397797B2 JP7397797B2 (ja) 2023-12-13

Family

ID=67548561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542552A Active JP7397797B2 (ja) 2018-02-07 2019-02-04 治療用化合物および組成物
JP2023203652A Pending JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023203652A Pending JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Country Status (10)

Country Link
US (2) US11691962B2 (https=)
EP (1) EP3749662A4 (https=)
JP (2) JP7397797B2 (https=)
KR (1) KR20200118088A (https=)
CN (1) CN111902404A (https=)
AU (1) AU2019217366B2 (https=)
BR (1) BR112020016123A2 (https=)
CA (1) CA3089970A1 (https=)
IL (2) IL276563B1 (https=)
WO (1) WO2019156929A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
EP3749662A4 (en) 2018-02-07 2021-07-14 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
EP1051431A1 (de) 1998-01-26 2000-11-15 Basf Aktiengesellschaft Thrombininhibitoren
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
AU752320B2 (en) 1998-06-25 2002-09-12 Bristol-Myers Squibb Company Amidino and guanidino azetidinone tryptase inhibitors
AU4654199A (en) 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
US20070032466A1 (en) 2003-08-22 2007-02-08 Teijin Pharma Limited Drug containing chymase inhibitor as the active ingredient
CA2648522A1 (en) * 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体
ES2674745T3 (es) 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrociclos como inhibidores del factor XIa
KR101937514B1 (ko) 2011-10-14 2019-01-10 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물
US9730921B2 (en) 2012-03-27 2017-08-15 Duke University Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
US20190315711A1 (en) 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP3749662A4 (en) 2018-02-07 2021-07-14 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS
KR20210084581A (ko) 2018-10-30 2021-07-07 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
WO2020092592A1 (en) 2018-10-30 2020-05-07 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP3917910A4 (en) 2019-01-29 2022-11-09 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Similar Documents

Publication Publication Date Title
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2004532250A (ja) 線維性疾患又は他の適応症の治療方法
US20210261524A1 (en) Therapeutic compounds and compositions
JP2015164972A5 (https=)
RU2017114933A (ru) Соединения и композиции для лечения или профилактики патологических состояний, связанных с избыточным отложением фибрина и/или образованием тромбов
RU2012144332A (ru) Циклоалкил-замещенное производное имидазола
JP2011527675A5 (https=)
JP2021512894A5 (https=)
JP2019529460A5 (https=)
JP2009521472A (ja) 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
JP2014500280A5 (https=)
JPH04503524A (ja) 再潅流損傷の防止又は制限のための薬剤
US20190315711A1 (en) Therapeutic compounds and compositions
US20210253550A1 (en) Therapeutic compounds and compositions
US20070259913A1 (en) Prophylaxis of thromboembolic events in cancer patients
JP2024023490A (ja) 治療用化合物および組成物
JPWO2019156929A5 (https=)
US20060241084A1 (en) Inhibition of vascular endothelial growth factor
CN101489549A (zh) 直接凝血酶抑制剂在心血管领域的新的适应症
CN108623591B (zh) 一种哌尼诺安化合物的用途
RU2813780C2 (ru) Терапевтические соединения и композиции
WO2004032911A2 (en) Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor
JP2015526493A (ja) 冠動脈バイパス移植術を受けることが予定されている患者の非st上昇型急性冠症候群の治療において使用するためのオタミキサバン
CN116134025A (zh) 酰胺膦氧类衍生物及其制备方法和用途
JPWO2020092594A5 (https=)